Share Tool

Same Medicine, Different Doses 

Kristina Hooper 

The Upshot 

7/15/2013 

For central banks globally, financial repression has become the prescribed antidote for high debt and little or no growth. But depending on the severity of their conditions, each economy will require a different amount of treatment, says Kristina Hooper.
Twitter

Get The Upshot
first on Twitter!

Follow AllianzGI_US on Twitter

Join the Conversation!

Kristina Hooper, CFP, CAIA, CIMA, ChFC, is US head of investment and client strategies for Allianz Global Investors. She has a B.A. from Wellesley College, a J.D. from Pace Law and an M.B.A. in finance from NYU, where she was a teaching fellow in macroeconomics.

Stocks posted gains again last week, propelled by reassuring words from Federal Reserve Chairman Ben Bernanke. The yield on the 10-year Treasury dropped while stocks rose to new highs, with the biggest gains coming from smaller-cap names.

Just as stock investors started coming to terms with the idea of tapering, Bernanke made some statements last week that sounded very dovish, suggesting it would take longer for tapering to begin than many market observers might expect. Specifically, he said, “both sides of our mandate are saying we need to be more accommodative.”

Bernanke's comments made me think of a country-western song by Dan Hicks entitled “How Can I Miss You If You Won't Go Away?” It's hard to think about life without quantitative easing when it seems likely to hang around in its entirety a lot longer than a few months.

But Bernanke's perspective does not necessarily reflect the mood of the entire FOMC. Notes from its mid-June meeting, released last week, show an equal split between those in favor of tapering in the near term and those opposed to it. We anticipate an end to the unwinding of QE by mid-2014, and we believe investors should continue to brace for it given the improvement we've seen in the US economy.

Triage Treatment

In many ways, central bankers are playing the role of a doctor nursing a sick patient back to good health. Part of that role is determining the right amount of medicine to administer to aid in the patient's recovery—and when to lower the dosage. But different patients require different doses. For example, the euro zone is in need of more critical care. With unemployment at more than 12% and an easy-money policy that has been counteracted by austerity policies in many nations, there continues to be a need for an extreme form of financial repression.

And it's not just Mario Draghi, president of the European Central Bank, saying it. Mark Carney, head of the Bank of England, has echoed this sentiment in recent weeks too. ECB Vice President Vitor Constancio explained it simply: "Europe is behind the US in economic recovery and inflation risks, which implies that monetary policy has to stay accommodative for a longer period of time."

Vital Signs Upshot Chart


Japan is in an entirely different hospital ward. To treat an economy that has been ailing for decades, it has received a bigger dose of financial repression through Abenomics. Following an encouraging Tankan report, an economic survey of Japanese businesses, and other positive signs, the Bank of Japan appears more confident that the country's economic recovery is underway.

Meanwhile, China, which had previously avoided medical treatment, may need to see a doctor. China just reported that its second-quarter gross domestic product expanded 7.5% from the year earlier, slower than its 7.7% growth rate in the first quarter. China's slowing economy has led to talk of whether its central bank should intervene and encourage the yuan to depreciate in order to support its struggling export sector.

Investors need to recognize that financial repression is a medicine widely prescribed to cure economic ills. While the dosage can be adjusted depending on a specific economy's symptoms, it's a treatment that's likely to be prescribed for the long term.

Subscribe Today The Upshot is available as a subscription for financial professionals only. New issues will be delivered via email every Monday. Your email address must be in our records for your subscription to take effect.




 
The material contains the current opinions of the author, which are subject to change without notice. Statements concerning financial market trends are based on current market conditions, which will fluctuate. References to specific securities and issuers are for illustrative purposes only and are not intended to be, and should not be interpreted as, recommendations to purchase or sell such securities. Forecasts and estimates have certain inherent limitations, and are not intended to be relied upon as advice or interpreted as a recommendation.

 
Past performance of the markets is no guarantee of future results. This is not an offer or solicitation for the purchase or sale of any financial instrument. It is presented only to provide information on investment strategies and opportunities.


A Word About Risk
: Equities have tended to be volatile, involve risk to principal and, unlike bonds, do not offer a fixed rate of return. Foreign markets may be more volatile, less liquid, less transparent and subject to less oversight, and values may fluctuate with currency exchange rates; these risks may be greater in emerging markets.
 

Allianz Global Investors Distributors LLC, 1633 Broadway, New York NY, 10019-7585, us.allianzgi.com, 1-800-926-4456.

Search

> Advanced Search

Find a Product

Or Select

Or Browse by

Contact Us

For all inquiries please contact us

Follow Us

       

Related Documents

TypeTitle
The Upshot-07.15.13 
Investor
The Upshot 
AGI-2013-07-15-7309 

Share

Facebook
LinkedIn
Twitter

You are currently leaving us.allianzgi.com and navigating to a third-party website. Allianz Global Investors Distributors LLC accepts no responsibility for content on third-party sites or for the services provided. When using the services provided by a third-party site, you are subject to that site’s terms of service and privacy rules, which you should review carefully.